

Deborah Forst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9853820/publications.pdf>

Version: 2024-02-01

22
papers

180
citations

1307594

7
h-index

1372567

10
g-index

22
all docs

22
docs citations

22
times ranked

231
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterizing Distress and Identifying Modifiable Intervention Targets for Family Caregivers of Patients with Malignant Gliomas. <i>Journal of Palliative Medicine</i> , 2023, 26, 17-27.	1.1	2
2	Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma. <i>Radiology</i> , 2022, 302, 410-418.	7.3	13
3	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. <i>Blood</i> , 2022, 139, 2306-2315.	1.4	62
4	Prognostic Awareness in Caregivers of Patients with Incurable Cancer. <i>Journal of Palliative Medicine</i> , 2021, 24, 561-569.	1.1	11
5	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. <i>Nature Cancer</i> , 2021, 2, 498-502.	13.2	26
6	QOLP-06. THE CHALLENGE OF FACING A NEW MALIGNANT GLIOMA DIAGNOSIS: PATIENT EXPERIENCES LEARNING ABOUT THEIR ILLNESS AND COMMUNICATING WITH THEIR PROVIDERS IN THE NEURO-ONCOLOGY CLINIC. <i>Neuro-Oncology</i> , 2021, 23, vi183-vi184.	1.2	0
7	BIOM-09. MYO-INOSITOL LEVELS ON MR SPECTROSCOPY CAN PREDICT FAILURE OF ANTI-ANGIOGENIC TREATMENT IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi11-vi12.	1.2	0
8	CTIM-30. PHASE II TRIAL OF PEMBROLIZUMAB IN RECURRENT AND RESIDUAL HIGH-GRADE MENINGIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi57-vi57.	1.2	0
9	QOLP-12. ILLNESS UNDERSTANDING AND PERCEPTIONS ABOUT PROGNOSIS IN PATIENTS WITH MALIGNANT GLIOMAS AND THEIR CAREGIVERS. <i>Neuro-Oncology</i> , 2021, 23, vi185-vi185.	1.2	0
10	TAMI-29. MR SPECTROSCOPY MEASURES OF LAC/NAA AND NAA/CHO DIFFERENTIATE SURVIVORSHIP IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH ANTI-ANGIOGENIC THERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi204-vi204.	1.2	0
11	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. <i>Neuro-Oncology</i> , 2021, 23, vi49-vi49.	1.2	0
12	Relationship Between Perceptions of Treatment Goals and Psychological Distress in Patients With Advanced Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 849-855.	4.9	18
13	QOLP-04. PILOT STUDY OF A VIDEOCONFERENCE-BASED PSYCHOLOGICAL INTERVENTION FOR FAMILY CAREGIVERS OF PATIENTS WITH MALIGNANT GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii175-ii175.	1.2	1
14	QOLP-17. FACTORS ASSOCIATED WITH PSYCHOLOGICAL DISTRESS IN CAREGIVERS OF PATIENTS WITH MALIGNANT GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi201-vi201.	1.2	0
15	RBTT-08. A RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2019, 21, vi220-vi220.	1.2	0
16	Hospice utilization in patients with malignant gliomas. <i>Neuro-Oncology</i> , 2018, 20, 538-545.	1.2	33
17	QOLP-23. PALLIATIVE CARE AND END OF LIFE HEALTHCARE UTILIZATION IN PATIENTS WITH INCURABLE PRIMARY MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi219-vi219.	1.2	0
18	RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi234-vi234.	1.2	4

#	ARTICLE	IF	CITATIONS
19	QOLP-21. THE RELATIONSHIP BETWEEN CAREGIVING BURDEN AND ANXIETY SYMPTOMS IN CAREGIVERS OF PATIENTS WITH MALIGNANT GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi219-vi219.	1.2	0
20	NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE. <i>Neuro-Oncology</i> , 2018, 20, vi191-vi191.	1.2	0
21	Survivorship care planning in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2018, 5, 3-9.	1.6	10
22	ACTR-57. TEXTILOMA-AN UNUSUAL MIMIC OF BRAIN TUMOR RECURRENCE: AÂCASE SERIES. <i>Neuro-Oncology</i> , 2016, 18, vi14-vi15.	1.2	0